Ashish Masih, MD
Neurology · Oklahoma City, OKNPI 1093857971
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,077 of the $157,779 with a category attached, or 88.8%. AbbVie accounts for 95.9% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2022 at $50,444 and has fallen 84.3% since, to $7,903 in 2025. Among neurology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $249.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$151K
- UCB, Inc.$665
- Lundbeck LLC$407
- Pfizer$407
- AstraZeneca$367
- Neurocrine Biosciences, Inc.$352
- plus $4K from 42 others
Across 2 payments — averaging $5150.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$10K
What the payments were for
- Speaking & faculty fees$140,07789%
- Travel & lodging$7,4745%
- Food & beverage$10,2286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,779 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 138 | $10,948 |
| Levetiracetam | 150 | $4,844 |
| Memantine Hcl | 178 | $4,420 |
| Gabapentin | 211 | $3,031 |
| Memantine Hcl ErMemantine Hcl | 11 | $2,013 |
| Primidone | 81 | $1,608 |
| Carbamazepine ErCarbamazepine | 12 | $1,521 |
| Donepezil Hcl | 177 | $1,146 |
| Pregabalin | 51 | $864 |
| Duloxetine Hcl | 38 | $803 |
| Carbamazepine | 16 | $642 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 47 | $575 |
| Lamotrigine | 37 | $408 |
| Topiramate | 44 | $373 |
| Phenobarbital | 21 | $285 |
Paid to pharmacies, not to this prescriber.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
- Tyler WebbOklahoma City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.